Literature DB >> 21119729

Anticancer drugs: Expanding the horizons of PARP inhibitors.

Teresa Villanueva.   

Abstract

Entities:  

Year:  2010        PMID： 21119729     DOI： 10.1038/nrd3335

Source DB:  PubMed          Journal:  Nat Rev Drug Discov        ISSN： 1474-1776            Impact factor:   84.694


× No keyword cloud information.
  1 in total

1.  Contextual synthetic lethality of cancer cell kill based on the tumor microenvironment.

Authors:  Norman Chan; Isabel M Pires; Zuzana Bencokova; Carla Coackley; Kaisa R Luoto; Nirmal Bhogal; Minalini Lakshman; Ponnari Gottipati; F Javier Oliver; Thomas Helleday; Ester M Hammond; Robert G Bristow
Journal:  Cancer Res       Date:  2010-10-05       Impact factor: 12.701
  1 in total
  2 in total

1.  Oral administration of naturally occurring chitosan-based nanoformulated green tea polyphenol EGCG effectively inhibits prostate cancer cell growth in a xenograft model.

Authors:  Naghma Khan; Dhruba J Bharali; Vaqar M Adhami; Imtiaz A Siddiqui; Huadong Cui; Sameh M Shabana; Shaker A Mousa; Hasan Mukhtar
Journal:  Carcinogenesis       Date:  2013-09-26       Impact factor: 4.944

2.  Synergistic interaction between cisplatin and PARP inhibitors in non-small cell lung cancer.

Authors:  Judith Michels; Ilio Vitale; Laura Senovilla; David P Enot; Pauline Garcia; Delphine Lissa; Ken A Olaussen; Catherine Brenner; Jean-Charles Soria; Maria Castedo; Guido Kroemer
Journal:  Cell Cycle       Date:  2013-02-21       Impact factor: 4.534
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.